- Home
- SEER vs ANIX Comparison
SEER vs ANIX Comparison
Compare SEER & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEER | ANIX |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 104.0M |
| IPO Year | 2020 | 1987 |
Fundamental Metrics
Financial Performance| Metric | SEER | ANIX |
|---|---|---|
| Price | $1.80 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 128.0K | ★ 233.0K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,376,999.00 | N/A |
| Revenue This Year | $22.37 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $1.62 | $2.33 |
| 52 Week High | $2.41 | $5.46 |
Technical Indicators
Market Signals| Indicator | SEER | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 38.73 | 36.65 |
| Support Level | $1.84 | $2.95 |
| Resistance Level | $1.92 | $3.14 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 8.25 |
Price Performance
Historical ComparisonAbout SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.